80 related articles for article (PubMed ID: 24716986)
1. Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Asian Pac J Cancer Prev; 2014; 15(5):2369-74. PubMed ID: 24716986
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
5. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.
Yang Y; Liu YH; Sun X; Yu MW; Yang L; Cheng PY; Yang GW; Wang XM
Curr Med Res Opin; 2017 Sep; 33(9):1663-1675. PubMed ID: 28665153
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
7. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
Jänne PA; Mann H; Ghiorghiu D
Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
[TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract][Full Text] [Related]
11. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
12. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis.
Wang WW; Wang WQ; Wang SS; Pan L
Ann Transl Med; 2022 May; 10(10):593. PubMed ID: 35722363
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment.
Jin Y; Sun Y; Shi X; Zhao J; Shi L; Hong W; Yu X
Clin Ther; 2014 Dec; 36(12):1980-1990. PubMed ID: 25256387
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
17. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
19. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
